Asymmetric Dimethylarginine, the Promoter Factor of Cardiovascular Pathologies

Romanian Journal of Medical Practice
doi 10.37897/rjmp.2019.3.10
Full Text
Abstract

Available in full text

Date
Authors
Publisher

AMALTEA Medical Publishing House

Related search

Cardiovascular Risk Factors and the Concentration of Asymmetric Dimethylarginine

Advances in Clinical and Experimental Medicine
BiochemistryMedicineGeneticsMolecular Biology
2020English

Asymmetric Dimethylarginine (ADMA) and Cardiovascular Disease: Insights From Prospective Clinical Trials

Vascular Medicine
MedicineCardiovascular MedicineCardiology
2005English

Asymmetric Dimethylarginine and Asthma

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2014English

Asymmetric Dimethylarginine (ADMA) Accelerates Cell Senescence

Vascular Medicine
MedicineCardiovascular MedicineCardiology
2005English

Metabolism of Asymmetric Dimethylarginine and Its Clinical Significance

Turkish Journal of Biochemistry
BiochemistryClinical BiochemistryMolecular Biology
2012English

GPCRs in Cardiovascular Pathologies

Drug Discovery Today: Disease Models
Drug DiscoveryMolecular Medicine
2012English

Plasma Asymmetric Dimethylarginine Levels in Healthy People

Folia Medica
Medicine
2011English

Asymmetric Dimethylarginine in the Maternal and Fetal Circulation in Preeclampsia

Pediatric Research
Child HealthPediatricsPerinatology
2009English

Homocysteine and Asymmetric Dimethylarginine (ADMA) in Neurological Diseases

JOURNAL OF ADVANCES IN CHEMISTRY
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy